LCM
ELEV

Landscape Capital Management’s Elevation Oncology ELEV Stock Holding History

Landscape Capital Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,999
Closed -$7.29K – 854
2023
Q3 		$7.29K Buy
+10,999
New +$11.1K ﹤0.01% 460

Other funds holding ELEV

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Landscape Capital Management's ELEV Position: Q4 2023 in Review

Landscape Capital Management sold out of Elevation Oncology (ELEV) in Q4 2023, closing a stake of 10,999 shares — an estimated $7.29K sold.

Landscape Capital Management first reported a position in ELEV in Q3 2023 and held it in 1 quarter. The position peaked at $7.29K in Q3 2023. 32 funds tracked by Wall St. Rank hold ELEV as of Q4 2023.

  • Landscape Capital Management reported no remaining Elevation Oncology position as of Q4 2023 after selling out during the quarter.
  • Landscape Capital Management sold 10,999 Elevation Oncology shares in Q4 2023, an estimated $7.29K.
  • Landscape Capital Management first reported a position in Elevation Oncology in Q3 2023 and held it in 1 quarter.
  • Landscape Capital Management's Elevation Oncology position peaked at $7.29K in Q3 2023.
  • 32 funds tracked by Wall St. Rank held Elevation Oncology as of Q4 2023.

Based on Landscape Capital Management's 13F filing for Q4 2023, filed 5 Feb 2024.